Making Sense of Cervical Cancer Screening Guidelines and Recommendations.

{"article_title":"Making Sense of Cervical Cancer Screening Guidelines and Recommendations.","author":"\"Davis, Michelle , Feldman, Sarah\"","journal_title":"Current treatment options in oncology","issn":"1534-6277 ; Electronic","isbn":"","publication_date":"20151201","volume":"16","issue":"12","first_page":"55","page_count":"","accession_number":"26467929","doi":"10.1007\/s11864-015-0373-1","publisher":"Current Science, Inc","doctype":"Journal Article","subjects":"Radiology ","interest_area":["Obstetrics & Gynecology"," Internal\/Family Medicine"],"abstract":"Since the publication of the American Cancer Society (ACS)\/American Society for Colposcopy and Cervical Pathology (ASCCP)\/American Society for Clinical Pathology (ASCP) clinical guidelines in 2012, the majority of practice organizations have reached a consensus on screening recommendations for a low-risk population. These guidelines were based on a thorough review of the evidence with reproducible methods to obtain high-quality, generalizable guidelines. Despite the strength of the evidence based recommendations comprising these guidelines, limitations in physician understanding and compliance remain with respect to reaching an unscreened population and defining and caring for women who are at \"high risk.\" \"High-risk\" patients are poorly characterized but should include women with a history of a prior abnormal screening, as data has shown a subsequent increased risk of cervical intraepithelial neoplasia grade 2 (CIN2) or greater, even after treatment. These women warrant more intense screening than the general population-though there are no evidence-based guidelines for optimized screening protocols in this population. Emerging data in cervical cancer screening this year includes the FDA approval of primary high-risk human papillomavirus (HPV) testing. While the data is promising, its role in clinical practice, impact on rates of colposcopy in a non-study population, and long-term outcomes are not fully understood, and ongoing research is needed. Challenges remain in this shifting environment on the optimal interval and modality for cervical cancer screening to provide the greatest benefit in detection of precancerous lesions while minimizing the harm of overtreatment. While rapid advancements in research provide improved knowledge on how to treat and prevent this disease, it is often difficult for providers across multiple specialties to remain abreast of these changes and to educate their patients about the most current recommendations. Ultimately, provider and patient education is critical both for improving primary prevention with HPV vaccination, as well as for the uptake of evidence-based screening and management guidelines aimed at detecting and treating precancerous changes of the cervix.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=26467929&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Davis M, Feldman S","Journal_Info":"Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100900946 Publication Model: Print Cited Medium: Internet ISSN: 1534-6277 (Electronic) Linking ISSN: 15346277 NLM ISO Abbreviation: Curr Treat Options Oncol Subsets: MEDLINE","Publication_Type":"Journal Article","Published_Date":"2015-12-01","Source":"Current treatment options in oncology [Curr Treat Options Oncol] 2015 Dec; Vol. 16 (12), pp. 55.","Languages":"English","Electronic_ISSN":"1534-6277","MeSH_Terms":"Early Detection of Cancer*, Papillomaviridae\/*pathogenicity , Papillomavirus Vaccines\/*therapeutic use , Uterine Cervical Neoplasms\/*therapy, Colposcopy ; Female ; Guidelines as Topic ; Humans ; Mass Screening ; Papillomaviridae\/immunology ; Papillomavirus Vaccines\/immunology ; United States ; Uterine Cervical Neoplasms\/immunology ; Uterine Cervical Neoplasms\/pathology ; Uterine Cervical Neoplasms\/virology","Subjects":"Colposcopy, Female, Guidelines as Topic, Humans, Mass Screening, Papillomaviridae immunology, Papillomavirus Vaccines immunology, United States, Uterine Cervical Neoplasms immunology, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms virology, Early Detection of Cancer, Papillomaviridae pathogenicity, Papillomavirus Vaccines therapeutic use, Uterine Cervical Neoplasms therapy","Title_Abbreviations":"Current treatment options in oncology","Volume":"16"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"26467929","RelevancyScore":"779","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"778.578125"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=26467929&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=26467929&authtype=shib&custid=ns346513&group=main&profile=eds"}